This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

BeneFIX (nonacog alfa) Prescribing Information for Great Britain click here. BeneFIX (nonacog alfa) Prescribing Information for Northern Ireland click here.
​​​​​​​
Adverse event reporting can be found at the bottom of this page.    

​​​​​​​BeneFIX® (nonacog alfa) is recombinant coagulation factor IX indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). BeneFIX® can be used for all age groups.1  

Purification

BeneFIX® (nonacog alfa) is manufactured and purified to be free from the risk of human blood-borne pathogen transmission.1–5

Albumin-free state-of-the-art manufacturing process

Albumin-free

Synthetic ligand

Nanofiltration

The BeneFIX® purification process  

BeneFIX® (nonacog alfa) manufacturing eliminates the risk of blood-borne pathogens including HIV, hepatitis virus, parvovirus, and variant Creutzfeldt-Jakob disease-causing prions.4    

​​​​​​​No animal or human plasma–derived protein is used during the manufacture or formulation of BeneFIX®.2  

Albumin-free

The process uses well-characterised host cells, no blood or plasma products and is free from exogenous human and animal proteins.2,4,5  

Synthetic ligand

The four-step chromatographic purification process does not require monoclonal antibodies.4,5  

Nanofiltration

Nanofiltration has been added as a virus removal step.4,5  

Manufacturing eliminates the risk of blood-borne pathogens, including:4  

• HIV  

• Hepatitis virus  

• Parvovirus  

• Prions that cause variant ​​​Creutzfeldt-Jakob disease  

Explore More

Heritage

BeneFIX® has more than 20 years’ experience in haemophilia B, building on a proud heritage in haemophilia care.1  

Learn more

How BeneFIX® works  

BeneFIX® (nonacog alfa) contains recombinant coagulation factor IX, which has functional characteristics comparable to those of endogenous factor IX.1  

Find out more

Safety profile

BeneFIX® has a well-documented safety profile in both adults and children.1  

Read more

** This is an optional area where footnotes can live.

Clinical efficacy

Access data on the clinical efficacy of BeneFIX® for on-demand treatment and prophylaxis.  

Find out more

** This is an optional area where footnotes can live.

Recommended dosing schedules1

No two days are the same. No two patients are the same. BeneFIX® offers frequent, flexible dosing so your patients are covered for everyday life.1,6,7 

Find out more

** This is an optional area where footnotes can live.


References
  1. BeneFIX® Summary of Product Characteristics. For Great Britain, available here. For Northern Ireland, available here.
  2. Lambert T et al. Haemophilia 2007;13:233–243.  
  3. Roth DA et al. Blood 2001;98(13):3600–3606.  
  4. Adamson S et al. Semin Hematol. 1998;35(2 Suppl 2):22–27.  
  5. Harrison S et al. Semin Hematol. 1998;35:4–10.  
  6. Shapiro AD et al. Haemophilia 2005;11:571–582.  
  7. Berntorp E, Andersson N. Semin Thromb Hemost. 2016;42:518–525.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
​​​​​​​Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

PP-BEN-GBR-0487. September 2021.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No